Data Demonstrating Power of Metastatic Niche and Patient-Specific Models in Oncology Drug Screening Studies Presented at 2020 AACR Virtual Annual Meeting II

First presentation of data using Cellaria’s proprietary patient-specific models of the tumor microenvironment used to study tumor growth, metastasis.

06/24/2020 WAKEFIELD, MA: Cellaria announces today it is presenting data on the value of modeling the metastatic niche, and the benefits of using patient-derived cancer cell models, mesenchymal stem cells (MSCs), and optimization of oxygen level and extracellular matrix (ECM) to study antitumor drug response, personalized therapy, and disease mechanisms. The data, featured in a poster at 2020 AACR Annual Meeting II, results from Cellaria’s spheroid system using five cancer cell models (pancreatic, lung adenocarcinoma, colon adenocarcinoma, endometrioid ovarian and high-grade serous carcinoma). With this 3D system, Cellaria is addressing an unmet need to improve predictions of the safety and efficacy of new drugs in preclinical testing and clinical trials.

By using patient-specific cell models, translational scientists are able to go beyond traditional cell lines, to address the complexity and individuality of the disease and identify treatments that better meet the needs of each patient.  Specificity in cell models enables researchers to derive the answers they need earlier in the drug development life cycle and with a continuous, direct connection to the patient.

“This data demonstrates the power of using patient specific cell models in a 3D format to model the tumor microenvironment and gain more actionable information from drug screening studies” comments David Deems, CEO, Cellaria Inc. “By using specific model patient populations that maintain their heterogeneity and individuality, users can test targets on our highly characterized cell models and select the mutation profile that is most important to their research.”

To see the data, please download the poster here. For more information on Cellaria Inc and its patient-specific cell models, please visit cellariainc.com or call 978-720-8051.

 

Download the Poster

 

About Cellaria Inc.

Cellaria Inc’s mission is to develop and build more informative disease cell models to revolutionize and accelerate the search for a cure. The company provides a suite of products and services that are actionable, replicable and that originate from a patient’s unique specimens. Cellaria’s solutions better enable disease researchers to select promising compounds and ultimately identify the most effective treatment for each patient’s needs. This helps lead the research community to more personalized therapeutics, revolutionizing and accelerating the search for a cure and/or personalized treatments.